Drug intelligence / Profile preview

melperone

Development stage
Phase 2
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral, Intramuscular, Intravenous
01

Overview

Melperone is an atypical antipsychotic of the butyrophenone chemical class and is structurally related to haloperidol. It has been used for over 30 years in the European Union for the treatment of sleep disorders, confusion states (especially in geriatric patients), psychomotor dysfunction associated with psychiatric and alcohol-dependent patients, severe agitation, schizophrenia-related psychosis (including treatment-resistant cases), anxiety disorders (with anxiolytic properties), and certain behavioral disorders. It is also considered for psychosis related to Parkinson’s disease. Melperone acts primarily as a dopamine D2 receptor antagonist with low affinity and rapid dissociation from D2 receptors; it also exerts effects on serotonin receptors (5-HT2A) contributing to its anxiolytic and mood-stabilizing effects. The drug is known for its relatively mild side effect profile compared to typical antipsychotics[1][3][7].

Brand names
BuronilEunerpanBunil
Other names
methylperonmetylperonMel-PurenMelneurinHarmosinLibernal
02

Targets

HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on melperone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on melperone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call